Evidence map›Paper›PMID 35448285›Full record

ReviewBiosensors2022

Plasmonic Metal Nanoparticles Hybridized with 2D Nanomaterials for SERS Detection: A Review.

Caterina Serafinelli, Alessandro Fantoni, Elisabete C B A Alegria, Manuela Vieira

Abstract readReview
In one paragraph

Review in Biosensors, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Rapid detection of SARS-CoV-2: The gradual boom of lateral flow immunoassay.Frontiers in bioengineering and biotechnology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Caterina SerafinelliInstituto Superior de Engenharia de Lisboa-Instituto Politécnico de Lisboa, 1949-014 Lisboa, Portugal.ORCID 0000-0003-2399-731X
Alessandro FantoniInstituto Superior de Engenharia de Lisboa-Instituto Politécnico de Lisboa, 1949-014 Lisboa, Portugal.ORCID 0000-0002-9938-0351
Elisabete C B A AlegriaInstituto Superior de Engenharia de Lisboa-Instituto Politécnico de Lisboa, 1949-014 Lisboa, Portugal.ORCID 0000-0003-4060-1057
Manuela VieiraInstituto Superior de Engenharia de Lisboa-Instituto Politécnico de Lisboa, 1949-014 Lisboa, Portugal.ORCID 0000-0002-1150-9895

Funding

Fundação para a Ciência e Tecnologia FCT - Fundação para a Ciência e Tecnologia
6 · The paper itself

Abstract

In SERS analysis, the specificity of molecular fingerprints is combined with potential single-molecule sensitivity so that is an attractive tool to detect molecules in trace amounts. Although several substrates have been widely used from early on, there are still some problems such as the difficulties to bind some molecules to the substrate. With the development of nanotechnology, an increasing interest has been focused on plasmonic metal nanoparticles hybridized with (2D) nanomaterials due to their unique properties. More frequently, the excellent properties of the hybrids compounds have been used to improve the drawbacks of the SERS platforms in order to create a system with outstanding properties. In this review, the physics and working principles of SERS will be provided along with the properties of differently shaped metal nanoparticles. After that, an overview on how the hybrid compounds can be engineered to obtain the SERS platform with unique properties will be given.

Indexed as

Metal NanoparticlesNanostructuresGoldNanotechnologySpectrum Analysis, RamanGoldhotspotshybrid materialsplasmonic metal nanoparticlesSERS analysis

Identifiers

PMID35448285
PMCPMC9029226

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.